Patients who discontinued cancer immunotherapy because of immune-related adverse events (irAEs) often had durable benefits ...

Lung cancer (LC) is a major global health issue, with high mortality rates and limited therapeutic options. It is primarily categorized into non-small cell lung cancer (NSCLC) and small cell lung ...

The first patient with small cell lung cancer has been dosed in a phase 1/2 trial investigating first-line iadademstat plus ...

The DAMO PANDA can accurately detect pancreatic cancer lesions, and FDA breakthrough therapy designation aims to accelerate ...

Mesothelioma and lung cancer are different conditions that can be caused by asbestos. Learn more about mesothelioma vs. lung ...

An experimental drug now in clinical trials as a cancer treatment could help boost the power of first-line tuberculosis (TB) ...

Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

Immunome's strong financial position supports ongoing clinical development and potential market entry for key assets. See why ...

Breast cancer is the most common cancer in women and the second leading cause of cancer-related deaths after lung cancer.

A new study suggests the cumulative effects of ionizing radiation from CT scans may raise a person's lifetime risk of ...

In a Johns Hopkins Children’s Center study, the addition of navitoclax to the standard TB treatment significantly increased ...

Recent research sheds light on how changes in the chemical structure of a protein called Interleukin-6 affect lung cancer’s ...